Auricle vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Neurostimulation implant for hearing restoration beyond hearing aids; targeting 3.5M US patients in the gap between aids and cochlear implants with Fogarty Innovation backing.
About
Auricle is a medical device company developing a neurostimulation implant designed to restore hearing for patients with moderate-to-severe hearing loss who no longer receive adequate benefit from conventional hearing aids — addressing a population of approximately 3.5 million patients in the US who have exhausted hearing aid options but may not qualify for or desire cochlear implants. Founded in 2020 in Mountain View, California and a Y Combinator W21 graduate, Auricle raised $500,000 from YC, Digilife, Fogarty Innovation, North South Ventures, and StartX, achieving $1.4 million in revenue in 2024 with 9 employees.\n\nAuricle's device uses electrical stimulation of the auditory nerve or cochlea in a minimally invasive implant procedure, providing amplification and sound clarity beyond what hearing aids can achieve by directly stimulating the neural pathway rather than amplifying acoustic sound. The device targets the significant gap between hearing aids (non-surgical, limited for severe loss) and cochlear implants (extensive surgery, full inner ear destruction) — offering a middle-ground intervention for patients with moderate-to-severe loss who want more than hearing aids provide. The $1.2 billion addressable market represents the unmet need in this underserved gap.\n\nIn 2025, Auricle is in the pre-market regulatory and clinical validation phase, working toward FDA clearance for its neurostimulation approach. The hearing device market is dominated by Cochlear Limited, Advanced Bionics (Sonova), and MED-EL for implantable hearing devices, alongside Starkey, Phonak, Oticon, and ReSound for hearing aids. Fogarty Innovation's backing indicates strong clinical mentorship — Fogarty is the leading medical device incubator associated with Thomas Fogarty, a legendary medical device inventor. The 2025-2026 strategy focuses on completing clinical studies demonstrating efficacy and safety, building the regulatory submission, and establishing clinical partnerships with ENT and audiology centers.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.